Charlie Brooker: Why Twitter is like Rock Band

"There’s a pressure to have an opinion on every incremental development on everything," he says.

I've interviewed Charlie Brooker for the New Statesman print magazine, but there was a quote of his from the interview that was so righteous, I had to blog it. I asked him whether he was currently using Twitter much less than before because he'd gone off it. 

He said:

I haven’t gone off it entirely. Because I’ve been so busy recently . . . When you don’t use it for a while, your brain calms down. So what I would do is lurk, and see what other people are doing . . . but when your rule is that you won't write anything, it's such a relief, it's like when you really need a piss and you finally have one. It’s like that happens in your brain.

You can see everyone getting very excited about 20 things a day, and you think, “Oh god, I don’t even have to have an opinion about that or even care that it matters”. And you start rather arrogantly looking on and thinking, “Yes, you’re all excited about that, you won't be in three hours' time”. There’s a pressure - if you are actively participating in it - there’s a pressure to have an opinion on every incremental development on everything. And there’s instant scandals and instant laughing stocks or talking points. And I just . . . it started making me feel ill. By which I mean in the head.

You know that feeling you get – you’ll recognise this as a gamer – that feeling when you spend hours playing a game – hours and hours and hours, and then you realise it's really late, it's like 3 or 4 [am] and you’ve got to be up at 8, and . .. you notice daylight breaking and you feel sort of disgusted and hollow, because actually you’ve not really done anything constructive. You’ve saved the world. A world that doesn’t exist.

Yeah, I can feel like I’ve rewired my optic nerve when I finish playing Rock Band.

Yeah, well, Twitter is actually a lot like Rock Band, but instead of coloured bars coming towards you, it's opinions on things. Topics. And there’s a pressure to respond. And then, the minute you stop doing that, you just think "oh, what is that about?" That makes me sound impossibly old. But I am.

Brooker has a new book out, by the way: I Can Make You Hate. It really can, you know. 

Rock Band, like Twitter, makes you press buttons quickly, says Charlie Brooker.

Helen Lewis is deputy editor of the New Statesman. She has presented BBC Radio 4’s Week in Westminster and is a regular panellist on BBC1’s Sunday Politics.

Getty Images/ Staff
Show Hide image

The answer to the antibiotics crisis might be inside your nose

The medical weapons we have equipped ourselves with are losing their power. But scientists scent an answer. 

They say there’s a hero in everyone. It turns out that actually, it resides within only about ten percent of us. Staphylococcus lugdunensis may be the species of bacteria that we arguably don’t deserve, but it is the one that we need.

Recently, experts have cautioned that we may be on the cusp of a post-antibiotic era. In fact, less than a month ago, the US Centres for Disease Control and Prevention released a report on a woman who died from a "pan-resistant" disease – one that survived the use of all available antibiotics. Back in 1945, the discoverer of penicillin, Alexander Fleming, warned during his Nobel Prize acceptance speech against the misuse of antibiotics. More recently, Britain's Chief Medical Officer Professor Dame Sally Davies has referred to anti-microbial resistance as “the greatest future threat to our civilisation”.

However, hope has appeared in the form of "lugdunin", a compound secreted by a species of bacteria found in a rather unlikely location – the human nose.

Governments and health campaigners alike may be assisted by a discovery by researchers at the University of Tubingen in Germany. According to a study published in Nature, the researchers had been studying Staphylococcus aureus. This is the bacteria which is responsible for so-called "superbug": MRSA. A strain of MRSA bacteria is not particularly virulent, but crucially, it is not susceptible to common antibiotics. This means that MRSA spreads quickly from crowded locations where residents have weaker immune systems, such as hospitals, before becoming endemic in the wider local community. In the UK, MRSA is a factor in hundreds of deaths a year. 

The researchers in question were investigating why S. aureus is not present in the noses of some people. They discovered that another bacteria, S. lugdunensis, was especially effective at wiping out its opposition, even MRSA. The researchers named the compound created and released by the S. lugdunensis "lugdunin".

In the animal testing stage, the researchers observed that the presence of lugdunin was successful in radically reducing and sometimes purging the infection. The researchers subsequently collected nasal swabs from 187 hospital patients, and found S. aureus on roughly a third of the swabs, and S. lugdunensis on up to 10 per cent of them. In accordance with previous results, samples that contained both species saw an 80 per cent decrease of the S. aureus population, in comparison to those without lugdunin.

Most notably, the in vitro (laboratory) testing phase provided evidence that the new discovery is also useful in eliminating other kinds of superbugs, none of which seemed to develop resistance to the new compound. The authors of the study hypothesised that lugdunin had evolved  “for the purpose of bacterial elimination in the human organism, implying that it is optimised for efficacy and tolerance at its physiological site of action". How it works, though, is not fully understood. 

The discovery of lugdunin as a potential new treatment is a breakthrough on its own. But that is not the end of the story. It holds implications for “a new concept of finding antibiotics”, according to Andreas Peschel, one of the bacteriologists behind the discovery.

The development of antibiotics has drastically slowed in recent years. In the last 50 years, only two new classes of this category of medication have been released to the market. This is due to the fact almost all antibiotics in use are derived from soil bacteria. By contrast, the new findings record the first occurrence of a strain of bacteria that exists within human bodies. Some researchers now suggest that the more hostile the environment to bacterial growth, the more likely it may be for novel antibiotics to be found. This could open up a new list of potential areas in which antibiotic research may be carried out.

When it comes to beating MRSA, there is hope that lugdunin will be our next great weapon. Peschel and his fellow collaborators are in talks with various companies about developing a medical treatment that uses lugdunin.

Meanwhile, in September 2016, the United Nations committed itself to opposing the spread of antibiotic resistance. Of the many points to which the UN signatories have agreed, possibly the most significant is their commitment to “encourage innovative ways to develop new antibiotics”. 

The initiative has the scope to achieve a lot, or dissolve into box ticking exercise. The discovery of lugdunin may well be the spark that drives it forward. Nothing to sniff about that. 

Anjuli R. K. Shere is a 2016/17 Wellcome Scholar and science intern at the New Statesman